Ratings for BrightSpring Health BTSG were provided by 9 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
---|---|---|---|---|---|
Total Ratings | 5 | 3 | 1 | 0 | 0 |
Last 30D | 1 | 0 | 0 | 0 | 0 |
1M Ago | 4 | 3 | 1 | 0 | 0 |
2M Ago | 0 | 0 | 0 | 0 | 0 |
3M Ago | 0 | 0 | 0 | 0 | 0 |
In the assessment of 12-month price targets, analysts unveil insights for BrightSpring Health, presenting an average target of $17.28, a high estimate of $26.00, and a low estimate of $11.50. A 33.54% drop is evident in the current average compared to the previous average price target of $26.00.
Exploring Analyst Ratings: An In-Depth Overview
The analysis of recent analyst actions sheds light on the perception of BrightSpring Health by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
---|---|---|---|---|---|
Jamie Perse | Goldman Sachs | Lowers | Buy | $23.00 | $26.00 |
Pito Chickering | Deutsche Bank | Announces | Hold | $11.50 | - |
Whit Mayo | Leerink Partners | Announces | Outperform | $15.00 | - |
Joanna Gajuk | B of A Securities | Announces | Buy | $14.00 | - |
A.J. Rice | UBS | Announces | Buy | $15.00 | - |
Stephen Baxter | Wells Fargo | Announces | Overweight | $15.00 | - |
Brian Tanquilut | Jefferies | Announces | Buy | $18.00 | - |
Erin Wright | Morgan Stanley | Announces | Overweight | $18.00 | - |
Jamie Perse | Goldman Sachs | Announces | Buy | $26.00 | - |
Key Insights:
- Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to BrightSpring Health. This information provides a snapshot of how analysts perceive the current state of the company.
- Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of BrightSpring Health compared to the broader market.
- Price Targets: Analysts navigate through adjustments in price targets, providing estimates for BrightSpring Health's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into BrightSpring Health's market standing. Stay informed and make well-considered decisions with our Ratings Table.
Stay up to date on BrightSpring Health analyst ratings.
If you are interested in following small-cap stock news and performance you can start by tracking it here.
About BrightSpring Health
BrightSpring Health Services Inc is a platform of complementary health services delivering provider and pharmacy solutions for complex populations in home and community settings. Its platform delivers clinical services and pharmacy solutions across Medicare, Medicaid, and commercially insured populations.
Financial Milestones: BrightSpring Health's Journey
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Revenue Growth: BrightSpring Health's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2023, the company achieved a revenue growth rate of approximately 13.88%. This indicates a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: BrightSpring Health's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of -5.79%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): BrightSpring Health's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of -18.93%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): BrightSpring Health's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of -2.39%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 5.98, caution is advised due to increased financial risk.
The Basics of Analyst Ratings
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.